One near-term rival is Johnson & Johnson's FcRn inhibitor nipocalimab, which started a phase 3 programme last December.

One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

Haematological cancers are a recognised potential side effect with Skysona and were already mentioned in a boxed warning on the gene therapy's approved labelling. The new label restricts use of the ...

A jury in the US has found that tech giant Meta illegally compromised the privacy of a US woman who shared her data with a ...

In Part Two, putting theory into practice is addressed.

In its second-quarter financial filing, Iovance said it was planning to shed 19% of its workforce of more than 630 in order ...

At ASCO 2025 in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Dr Jason Williams, director of interventional ...

The smartphone-based CT-155 app, co-developed by Click Therapeutics and Boehringer Ingelheim, was able to help users achieve ...

The joint information sharing agreement between the medicines regulatory authority and reimbursement agency was first ...

Strand Therapeutics has raised $153 million in second-round financing that will be used to move its programmable mRNA ...